alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
[Federal Register Volume 89, Number 16 (Wednesday, January 24, 2024)]
[Notices]
[Page 4613]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-01287]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Heart, Lung, and Blood Institute; Notice of Closed 
Meeting

    Pursuant to section 1009 of the Federal Advisory Committee Act, as 
amended, notice is hereby given of the following meeting.
    The meeting will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The grant applications and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the grant applications, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: Heart, Lung, and Blood Initial Review Group; 
Clinical Trials Review Study Section.
    Date: February 29, 2024.
    Time: 9:00 a.m. to 5:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institutes of Health, Rockledge I, 6705 
Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).
    Contact Person: Keary A. Cope, Ph.D., Scientific Review Officer, 
Office of Scientific Review/DERA, National Heart, Lung, and Blood 
Institute, National Institutes of Health, 6705 Rockledge Drive, Room 
209-A, Bethesda, MD 20892-7924, (301) 827-7912, <a href="/cdn-cgi/l/email-protection#f1929e81949a90b19c90989ddf9f9899df969e87"><span class="__cf_email__" data-cfemail="3d5e524d58565c7d505c545113535455135a524b">[email protected]</span></a>.

(Catalogue of Federal Domestic Assistance Program Nos. 93.233, 
National Center for Sleep Disorders Research; 93.837, Heart and 
Vascular Diseases Research; 93.838, Lung Diseases Research; 93.839, 
Blood Diseases and Resources Research, National Institutes of 
Health, HHS)

    Dated: January 18, 2024.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2024-01287 Filed 1-23-24; 8:45 am]
BILLING CODE 4140-01-P


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>
##### Table of Contents



UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
 Washington, D.C. 20549
 FORM 8-K
 CURRENT REPORT
 Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
 Date of Report (Date of earliest event reported)
 April 1, 2008
 CERADYNE, INC.
  Delaware
    
    000-13059
    
    33-0055414(State or other jurisdiction of
    
    (Commission File Number)
    
    (IRS Employer Identification No.)incorporation)
 3169 Red Hill Avenue, Costa Mesa,
CA
    
    92626(Address of principal executive offices)
    
    (Zip Code)
   o
    
    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 o
    
    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 o
    
    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 o
    
    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))




---



TABLE OF CONTENTS  Item 7.01 Regulation FD DisclosureItem 9.01 Financial Statements and ExhibitsSIGNATURESEXHIBIT INDEXEXHIBIT 99.1    Table of Contents  
 Item 7.01 Regulation FD Disclosure.
   
 Item 9.01 Financial Statements and Exhibits.
 (d) Exhibits.
 Exhibit Number
    
    Description99.1
    
    Press release of Ceradyne, Inc. dated April 1, 2008.
 2




---



##### Table of Contents



SIGNATURES
  CERADYNE, INC.April 2, 2008
    By:
    /s/ Jerrold J. PellizzonJerrold J. PellizzonChief Financial Officer and Secretary 3




---



##### Table of Contents



EXHIBIT INDEX
 Exhibit Number
    
    Description99.1
    
    Press release of Ceradyne, Inc. dated April 1, 2008.
 4
Exhibit 10.21

2011 Bonus Plan

Purpose:

The Compensation Committee (the Compensation Committee) of the Board of Directors (the Board) of Medivation, Inc.
(the Company) has established the terms of the 2011 Bonus Plan (the Plan) to compensate the executive officers of the Company for the level of achievement of corporate performance objectives set forth by the Compensation
Committee for the 2011 fiscal year, as well as the executive officers contributions toward the achievement of those performance objectives.

Determination of 2011 Cash Bonuses:

Target bonuses for the Companys
named executive officers under the Plan will range from 50% to 65% of such executives 2011 base salary. The amount of cash bonuses, if any, for each named executive officer will be based on the named executive officer and the Company meeting
the 2011 corporate performance objectives approved by the Compensation Committee, which include objectives relating to clinical trial, regulatory and research and development activities and milestones, as well as objectives relating to the
Companys intellectual property. The Board and Compensation Committee reserve the right to modify these goals and criteria at any time or to grant bonuses to the participants even if the performance goals are not met. The target bonuses for the
Companys named executive officers for the 2011 fiscal year are as follows:



|                   |  |                                                 |      |  
|------------------ |  | ----------------------------------------------- | ---- | -
|Executive Officer  |  | Target Bonus(as percent 
of FY2011 Base Salary) |     
|David Hung, M.D.   |  |                                                 | 65.0 | %
|Lynn Seely, M.D.   |  |                                                 | 50.0 |  
|C. Patrick Machado |  |                                                 | 50.0 |  
|Rohan Palekar      |  |                                                 | 50.0 |
Update on Greenhouse GasPermitting ActivitiesAnna Marie WoodActing Director, Air Quality Policy Division, OAQPSClean Air Act Advisory CommitteeWashington, D.C.October 6, 2010Status of GHG PSD Permitting Guidance• Currently at OMB undergoing interagency review, timing for completion ofreview hopefully in near future; however specific timing uncertain.• EPA will provide public comment opportunity on guidance, once issued. Willfocus review on comments on the guidance pertaining to calculation and/orother technical errors that are submitted.• Will consider other comments as we move forward, do not intend to respondto comments, not a formal rulemaking action.• EPA will continue to closely monitor guidance implementation post Jan2011 and provide clarifications and supplement as needed.• EPA will assess whether additional guidance is needed, depending onimplementation experience2GHG Permitting Resources•One Stop Shopping GHG PSD Permitting Website:which will includefollowing policy technical, and other information:–GHG PSD Permitting Guidance–ORD GHG Mitigation Strategies Database• Including performance and cost data on current/developing GHGcontrol measures• Current focus on EGUs and cement plants–RACT/BACT/LAER Clearinghouse Enhancements• Formatting improvements to include GHG control and test data,links to State permits, GHG message board, etc.3GHG Permitting Resources–GHG Control Measures White Papers• Summarizes technical information on sector-specific control options• EGU, Cement, Refineries, Iron and Steel, Pulp and Paper, IndustrialBoilers, Nitric Acid Plants–Information about the EPA GHG Permitting Action Team• Name, email and phone number for points of contacts foreach Region on GHG PSD permitting questions•Training and outreach materials under development4
NUMBER 13-11-00179-CV

COURT OF APPEALS

THIRTEENTH DISTRICT OF TEXAS

CORPUS CHRISTI - EDINBURG

____________________________________________________________

BEVERLY PIRKLE AND STEPHEN O. PIRKLE, Appellants,

v.

U.S. BANK NATIONAL ASSOCIATION ND

D/B/A ELAN FINANCIAL SERVICES, Appellee.

____________________________________________________________

On Appeal from the 2nd 25th District Court 

of Gonzales County, Texas.

____________________________________________________________

MEMORANDUM OPINION

Before Chief Justice Valdez and Justices Garza and Vela

Memorandum Opinion Per Curiam

Appellants, Beverly Pirkle and Stephen O. Pirkle, perfected an appeal from a 

judgment entered by the 2nd 25th District Court of Gonzales County, Texas, in cause 

number 24,180. Appellants have filed a motion to dismiss the appeal with prejudice on 
2

grounds that the parties have reached an agreement to settle and compromise their 

differences. Appellants request that this Court dismiss the appeal with prejudice.

The Court, having considered the documents on file and appellants’ amended 

motion to dismiss the appeal, is of the opinion that the motion should be granted. See

TEX. R. APP. P. 42.1(a). Appellants’ amended motion to dismiss is granted, and the 

appeal is hereby DISMISSED WITH PREJUDICE. In accordance with the agreement of 

the parties, costs are taxed against the party incurring same. See TEX. R. APP. P. 42.1(d) 

("Absent agreement of the parties, the court will tax costs against the appellant."). 

Having dismissed the appeal at appellants’ request, no motion for rehearing will be 

entertained, and our mandate will issue forthwith.

PER CURIAM

Delivered and filed the

30th day of August, 2012.
EXHIBIT
23 PARITZ & COMPANY,
P.A.
CERTIFIED PUBLIC ACCOUNTANTS CONSENT
OF INDEPENDENT AUDITORS We
have issued our report dated April 4, 2007, accompanying the financial
statements of Trimol Group, Inc. to be contained in the Annual Report on Form
10-KSB (the 10-KSB) for Trimol Group, Inc., a Delaware corporation, for its
fiscal year ended December 31, 2006. We consent to the use of the
aforementioned report in the 10-KSB and to the use of our name as it appears
therein. /s/ Paritz
  & Company, P.A.PARITZ & COMPANY, P.A.Certified
  Public AccountantsDated: April
  17, 2007 33
EXHIBIT32

 

CERTIFICATIONPURSUANT TO

18U.S.C. SECTION1350,

ASADOPTED PURSUANT TO

SECTION906 OF THE SARBANES-OXLEY ACT OF 2002

 

Inconnection with the Quarterly Report of Fortis Enterprises (the"Company") on Form 10-QSB for the period ended March 31, 2004, asfiled with the Securities and Exchange Commission on the date hereof (the"Report"), I, Stephen W. Carnes, President and Chief Executive Officerof the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuantto Section 906 of the Sarbanes-Oxley Act of 2002, that:

 

(1)The Report fully complies with the requirements of Section 13(a) or 15(d) of theSecurities Exchange Act of 1934; and

 

(2)The information contained in the Report fairly presents, in all materialrespects, the financial condition and results of operations of the Company.

 

 

/S/StephenW. Carnes

StephenW. Carnes

Presidentand Chief Executive Officer

May 14, 2004
##### Table of Contents



UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
 Washington, D.C. 20549
 FORM 8-K
 CURRENT REPORT
 Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of the earliest event reported): March 17, 2008
 Valeant Pharmaceuticals International
  Delaware
    
    1-11397
    
    33-0628076(State or other jurisdiction of 
incorporation or organization)
    
    (Commission File Number)
    
    (I.R.S Employer
Identification No.)
 One Enterprise
Aliso Viejo, California 92656
 (949) 461-6000
  o
    
    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)o
    
    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)o
    
    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))o
    
    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))




---



TABLE OF CONTENTS  Item 8.01. Other EventsItem 9.01. Financial Statements and ExhibitsSIGNATURESEXHIBIT INDEXEXHIBIT 99.1    Table of Contents  
 Item 8.01. Other Events.
  
 Item 9.01. Financial Statements and Exhibits.
  Exhibit
    
    Description99.1
    
    Press release dated March 17, 2008.




---



##### Table of Contents



SIGNATURES
  Date: March 17, 2008
    VALEANT PHARMACEUTICALS INTERNATIONALBy:
    /s/ Eileen C. PruetteEileen C. PruetteExecutive Vice President, General Counsel




---



##### Table of Contents



EXHIBIT INDEX
 Exhibit Number
    
    Description99.1
    
    Press release dated March 17, 2008.
STEAM ELECTRIC CBI REPLACEMENT PAGE 

EPA-HQ-OW-2009-0819 

DCN: SE03501

THE FOLLOWING HAS BEEN REMOVED BECAUSE IT 

CONTAINS CONFIDENTIAL BUSINESS INFORMATION 

(CBI) PER 40 CFR PART 2, SUBPART B.
<TABLE> <S> <C>

<ARTICLE> 5
       
<S>                             <C>
<PERIOD-TYPE>                   6-MOS
<FISCAL-YEAR-END>                          JUN-30-1997
<PERIOD-START>                             JUL-01-1996
<PERIOD-END>                               DEC-31-1996
<CASH>                                      53,273,491
<SECURITIES>                                17,595,922
<RECEIVABLES>                               12,595,726
<ALLOWANCES>                                   286,982
<INVENTORY>                                  8,335,963
<CURRENT-ASSETS>                            92,612,643
<PP&E>                                       6,514,275
<DEPRECIATION>                               2,957,835
<TOTAL-ASSETS>                              99,119,127
<CURRENT-LIABILITIES>                        5,584,986
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                         9,152
<OTHER-SE>                                  93,524,989
<TOTAL-LIABILITY-AND-EQUITY>                99,119,127
<SALES>                                     22,073,068
<TOTAL-REVENUES>                            22,073,068
<CGS>                                        9,664,789
<TOTAL-COSTS>                               19,682,314
<OTHER-EXPENSES>                               700,746
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                         (1,679,587)
<INCOME-PRETAX>                              3,369,595
<INCOME-TAX>                                   964,190
<INCOME-CONTINUING>                          2,405,405
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                 2,405,405
<EPS-PRIMARY>                                     0.24
<EPS-DILUTED>                                     0.24
        

</TABLE>
**Exhibit
      32.1**





**Certification
      of the Chief Executive Officer**


**Pursuant
      to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the
      Sarbanes-Oxley Act of 2002**





I,
      Stephen Brock, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant
      to Section 906 of the Sarbanes-Oxley Act of 2002, that the Quarterly Report
      of
      Public Company Management Corporation on Form 10-QSB/A for the quarterly period
      ended March 31, 2006, fully complies with the requirements of Section 13(a)
      or
      15(d) of the Securities Exchange Act of 1934 and that information contained
      in
      such Form 10-QSB/A fairly presents in all material respects the financial
      condition and results of operations of Public Company Management
      Corporation.





Date:
      December 8, 2006





By: /s/
      Stephen
      Brock


Stephen
      Brock,


Chief
      Executive Officer
Electronically Filed

Intermediate Court of Appeals

CAAP-13-0005700

23-FEB-2015

08:08 AM
**Exhibit 32.2**

 

**CERTIFICATION PURSUANTTO18 U.S.C. §1350,AS ADOPTED PURSUANT TOSECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

 

In connection with the quarterly reportof Lawson Software, Inc. (the “Company”) on Form 10-Q for the periodended February 28, 2006 as filed with the Securities and Exchange Commission onthe date hereof (the “Report”), I, Robert G. Barbieri, Executive Vice Presidentand Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C.§1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of2002, that:

 

1.               TheReport fully complies with the requirements of Section 13(a) or 15(d) ofthe Securities Exchange Act of 1934; and

 

2.               Theinformation contained in the Report fairly presents, in all material respects,the financial condition and results of operations of the Company.

 

 
|   | /s/ ROBERT G. BARBIERI                                                                       |   |
|--------|----------------------------------------------------------------------------------------------|--------|
|   | Robert  G. Barbieri *Executive Vice President   and Chief Financial and Performance Officer* |
|   |                                                                                         |
|   | April  7, 2006                                                                               |

 

1

----
**Exhibit 31.1****CERTIFICATION**     I, Eric A. Danziger, President and Chief Executive Officer of ZipRealty, Inc., certify that: 1. I have reviewed this quarterly report on Form 10-Q of ZipRealty, Inc.;  2. Based on my knowledge, this report does not contain any untrue statement of a materialfact or omit to state a material fact necessary to make the statements made, in light ofthe circumstances under which such statements were made, not misleading with respect tothe period covered by this report;  3. Based on my knowledge, the financial statements, and other financial informationincluded in this report, fairly present in all material respects the financial condition,results of operations and cash flows of the registrant as of, and for, the periodspresented in this report;  4. The registrant’s other certifying officer(s) and I are responsible for establishing andmaintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e)and 15d-15(e)) for the registrant and have: a) Designed such disclosure controls and procedures, or caused such disclosurecontrols and procedures to be designed under our supervision, to ensure that materialinformation relating to the registrant, including its consolidated subsidiaries, ismade known to us by others within those entities, particularly during the period inwhich this report is being prepared;  b) Evaluated the effectiveness of the registrant’s disclosure controls and proceduresand presented in this report our conclusion about the effectiveness of the disclosurecontrols and procedures, as of the end of the period covered by this report based onsuch evaluation; and  c) Disclosed in this report any change in the registrant’s internal control overfinancial reporting that occurred during the registrant’s most recent fiscal quarter(the registrant’s fourth quarter in the case of an annual report) that has materiallyaffected, or is reasonably likely to materially affect, the registrant’s internalcontrol over financial reporting; and 5. The registrant’s other certifying officer(s) and I have disclosed, based on our mostrecent evaluation of internal control over financial reporting, to the registrant’sauditors and the audit committee of the registrant’s board of directors (or personsperforming the equivalent functions): a) All significant deficiencies and material weaknesses in the design or operation ofinternal control over financial reporting which are reasonably likely to adverselyaffect the registrant’s ability to record, process, summarize and report financialinformation; and  b) Any fraud, whether or not material, that involves management or other employees whohave a significant role in the registrant’s internal control over financial reporting.        Date:November 10, 2005 By:  /s/ Eric A. Danziger    Eric A. Danziger    President and Chief Executive Officer
#### Horace GANT, Plaintiff-Appellant, v. DEPARTMENT OF CORRECTIONS; Roy Cooper, Attorney General for the State of North Carolina, Defendants-Appellees.

No. 02-7785.

United States Court of Appeals, Fourth Circuit.

Submitted Feb. 6, 2003.

Decided Feb. 12, 2003.

Horace Gant, Appellant Pro Se.

Before WILKINS, MICHAEL, and SHEDD, Circuit Judges.

Affirmed by unpublished PER CURIAM opinion.

PER CURIAM.

Horace Gant appeals the district court's orders dismissing his 42 U.S.C. § 1983 (2000) complaint as frivolous; and denying his Fed.R.Civ.P. 60(b) motion. We have reviewed the record and find no reversible error. Accordingly, we affirm on the reasoning of the district court. *See Gant v. Dep’t of Corr.,*No. CA-02-627-5-H (E.D.N.C. filed Sept. 27, 2002 *&*entered Oct. 1, 2002; filed Nov. 4, 2002 & entered Nov. 5, 2002). We dispense with oral argument because the facts and legal contentions are adequately presented in the ma*696terials before the court and argument would not aid the decisional process.

*AFFIRMED.*
Exhibit
      32.2






**CERTIFICATION
      PURSUANT TO**


**18
      U.S.C. SECTION 1350,**


**AS
      ADOPTED PURSUANT TO**


**SECTION
      906 OF THE SARBANES-OXLEY ACT OF 2002**






In
      connection with the Quarterly Report of GlobeTrac Inc. (the “Registrant”) on
      Form 10-QSB for the period ending March 31, 2007 as filed with the Securities
      and Exchange Commission on the date hereof (the “Report”), I, John daCosta,
      Secretary, Treasurer, and Chief Financial Officer of the Company, certify,
      pursuant to s.906 of the Sarbanes-Oxley Act of 2002, that:




(1)
        The Quarterly Report on Form 10-QSB fully complies with the requirements
      of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and




(2)
        The information contained in the Report fairly represents, in all
      material respects, the financial condition and result of operations of the
      Registrant.




/s/ John
              daCostaJohn daCosta
              Chief
                  Financial Officer




May
      15,
      2007
Exhibit 32.1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER

PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

I, J. Patrick Lashinsky, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley
Act of 2002, that the Quarterly Report of ZipRealty, Inc. on Form 10-Q for the three months ended June 30, 2010 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that information
contained in such Quarterly Report on Form 10-Q fairly presents in all material respects the financial condition and results of operations of ZipRealty, Inc.



|                     |  |     |  |                                      
|-------------------- |  | --- |  | -------------------------------------
|Date: August 4, 2010 |  | By: |  | /s/    J. Patrick Lashinsky          
|                     |  |     |  | J. Patrick Lashinsky                 
|                     |  |     |  | Chief Executive Officer and President

A signed original of this written statement required by Section 906 has been provided by ZipRealty, Inc. and will be retained by
ZipRealty, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.
Exhibit 23.1


                        Consent of independent auditors


We consent to the incorporation by reference in the Registration Statement (Form
S-8,  No.333-15219)  pertaining to the Open Plan Systems, Inc. 1996 Stock Option
Plan for  Non-Employee  Directors  of our report dated  February 12, 1999,  with
respect to the  consolidated  financial  statements of Open Plan  Systems,  Inc.
included in the Annual  Report  (Form  10-KSB) for the year ended  December  31,
1998.


                                                               /s/ ERNST & YOUNG

Richmond, Virginia
March 26, 1999